Puromycin Dihydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H561474

CAS#: 58-58-2

Description: Puromycin Dihydrochloride is an antibiotic. It inhibits protein synthesis by binding to RNA. Puromycin Dihydrochloride has antimicrobial, antitrypanosomal, and antineoplastic properties.


Chemical Structure

img
Puromycin Dihydrochloride
CAS# 58-58-2

Theoretical Analysis

Hodoodo Cat#: H561474
Name: Puromycin Dihydrochloride
CAS#: 58-58-2
Chemical Formula: C22H31Cl2N7O5
Exact Mass: 0.00
Molecular Weight: 544.430
Elemental Analysis: C, 48.54; H, 5.74; Cl, 13.02; N, 18.01; O, 14.69

Price and Availability

Size Price Availability Quantity
50mg USD 200 2 Weeks
100mg USD 330 2 Weeks
500mg USD 710 2 Weeks
Bulk inquiry

Synonym: Puromycin Dihydrochloride; Puromycin 2HCl;

IUPAC/Chemical Name: (2S)-2-Amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide dihydrochloride

InChi Key: MKSVFGKWZLUTTO-FZFAUISWSA-N

InChi Code: InChI=1S/C22H29N7O5.2ClH/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12;;/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32);2*1H/t14-,15+,16+,18+,22+;;/m0../s1

SMILES Code: O=C(N[C@@H]1[C@@H](CO)O[C@@H](N2C=NC3=C(N(C)C)N=CN=C23)[C@@H]1O)[C@@H](N)CC4=CC=C(OC)C=C4.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, ethanol, methanol, and water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 544.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Stepanenko AA, Heng HH. Transient and stable vector transfection: Pitfalls, off-target effects, artifacts. Mutat Res. 2017 Jul;773:91-103. doi: 10.1016/j.mrrev.2017.05.002. Epub 2017 May 16. Review. PubMed PMID: 28927539.

2: Burford JL, Gyarmati G, Shirato I, Kriz W, Lemley KV, Peti-Peterdi J. Combined use of electron microscopy and intravital imaging captures morphological and functional features of podocyte detachment. Pflugers Arch. 2017 Aug;469(7-8):965-974. doi: 10.1007/s00424-017-2020-0. Epub 2017 Jun 29. Review. PubMed PMID: 28664407; PubMed Central PMCID: PMC5553195.

3: Dinos GP, Athanassopoulos CM, Missiri DA, Giannopoulou PC, Vlachogiannis IA, Papadopoulos GE, Papaioannou D, Kalpaxis DL. Chloramphenicol Derivatives as Antibacterial and Anticancer Agents: Historic Problems and Current Solutions. Antibiotics (Basel). 2016 Jun 3;5(2). pii: E20. doi: 10.3390/antibiotics5020020. Review. PubMed PMID: 27271676; PubMed Central PMCID: PMC4929435.

4: Drainas D. Antibiotics and RNase P. Antibiotics (Basel). 2016 May 6;5(2). pii: E15. doi: 10.3390/antibiotics5020015. Review. PubMed PMID: 27164152; PubMed Central PMCID: PMC4929430.

5: Bertelli R, Bonanni A, Di Donato A, Cioni M, Ravani P, Ghiggeri GM. Regulatory T cells and minimal change nephropathy: in the midst of a complex network. Clin Exp Immunol. 2016 Feb;183(2):166-74. doi: 10.1111/cei.12675. Epub 2015 Oct 12. Review. PubMed PMID: 26147676; PubMed Central PMCID: PMC4711159.

6: Fukusumi Y, Miyauchi N, Hashimoto T, Saito A, Kawachi H. Therapeutic target for nephrotic syndrome: Identification of novel slit diaphragm associated molecules. World J Nephrol. 2014 Aug 6;3(3):77-84. doi: 10.5527/wjn.v3.i3.77. Review. PubMed PMID: 25332898; PubMed Central PMCID: PMC4202494.

7: Agrawal N, Brown MA. Genetic associations and functional characterization of M1 aminopeptidases and immune-mediated diseases. Genes Immun. 2014 Dec;15(8):521-7. doi: 10.1038/gene.2014.46. Epub 2014 Aug 21. Review. PubMed PMID: 25142031.

8: Dever TE, Gutierrez E, Shin BS. The hypusine-containing translation factor eIF5A. Crit Rev Biochem Mol Biol. 2014 Sep-Oct;49(5):413-25. doi: 10.3109/10409238.2014.939608. Epub 2014 Jul 17. Review. PubMed PMID: 25029904; PubMed Central PMCID: PMC4183722.

9: Hitzerd SM, Verbrugge SE, Ossenkoppele G, Jansen G, Peters GJ. Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids. 2014 Apr;46(4):793-808. doi: 10.1007/s00726-013-1648-0. Epub 2014 Jan 3. Review. PubMed PMID: 24385243.

10: de Mik SM, Hoogduijn MJ, de Bruin RW, Dor FJ. Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models. BMC Nephrol. 2013 Apr 1;14:74. doi: 10.1186/1471-2369-14-74. Review. PubMed PMID: 23547922; PubMed Central PMCID: PMC3637050.

11: Chopra A. (44)Sc-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid–conjugated puromycin. 2013 Jan 28 [updated 2013 Feb 28]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK126078/ PubMed PMID: 23469380.

12: Nagarajan NA, Shastri N. Immune surveillance for ERAAP dysfunction. Mol Immunol. 2013 Sep;55(2):120-2. doi: 10.1016/j.molimm.2012.10.006. Epub 2013 Feb 20. Review. PubMed PMID: 23433779; PubMed Central PMCID: PMC3612377.

13: Goodman CA, Hornberger TA. Measuring protein synthesis with SUnSET: a valid alternative to traditional techniques? Exerc Sport Sci Rev. 2013 Apr;41(2):107-15. doi: 10.1097/JES.0b013e3182798a95. Review. PubMed PMID: 23089927; PubMed Central PMCID: PMC3951011.

14: Chao JA, Yoon YJ, Singer RH. Imaging translation in single cells using fluorescent microscopy. Cold Spring Harb Perspect Biol. 2012 Nov 1;4(11). pii: a012310. doi: 10.1101/cshperspect.a012310. Review. PubMed PMID: 22960595; PubMed Central PMCID: PMC3536344.

15: Svenningsen P, Skøtt O, Jensen BL. Proteinuric diseases with sodium retention: Is plasmin the link? Clin Exp Pharmacol Physiol. 2012 Jan;39(1):117-24. doi: 10.1111/j.1440-1681.2011.05524.x. Review. PubMed PMID: 21466573.

16: Peer WA. The role of multifunctional M1 metallopeptidases in cell cycle progression. Ann Bot. 2011 May;107(7):1171-81. doi: 10.1093/aob/mcq265. Epub 2011 Jan 21. Review. PubMed PMID: 21258033; PubMed Central PMCID: PMC3091800.

17: Van Hateren A, James E, Bailey A, Phillips A, Dalchau N, Elliott T. The cell biology of major histocompatibility complex class I assembly: towards a molecular understanding. Tissue Antigens. 2010 Oct;76(4):259-75. doi: 10.1111/j.1399-0039.2010.01550.x. Review. Erratum in: Tissue Antigens. 2010 Nov;76(5):428. PubMed PMID: 21050182.

18: Kodama Y, Fujishima M. Secondary symbiosis between Paramecium and Chlorella cells. Int Rev Cell Mol Biol. 2010;279:33-77. doi: 10.1016/S1937-6448(10)79002-X. Epub 2010 Jan 29. Review. PubMed PMID: 20797676.

19: Yan S, Zhang Y, Lu H, Dong X, Tang C, Mu J. [In vitro display technologies]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2009 Dec;26(6):1367-71. Review. Chinese. PubMed PMID: 20095505.

20: Cybulsky AV. Endoplasmic reticulum stress in proteinuric kidney disease. Kidney Int. 2010 Feb;77(3):187-93. doi: 10.1038/ki.2009.389. Epub 2009 Oct 7. Review. PubMed PMID: 19812538.